Maze Therapeutics Statistics
Total Valuation
MAZE has a market cap or net worth of $1.43 billion. The enterprise value is $1.12 billion.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MAZE has 55.25 million shares outstanding. The number of shares has increased by 1,474.04% in one year.
| Current Share Class | 55.25M |
| Shares Outstanding | 55.25M |
| Shares Change (YoY) | +1,474.04% |
| Shares Change (QoQ) | +16.64% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 55.19% |
| Float | 33.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 122.99 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 4.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.50, with a Debt / Equity ratio of 0.07.
| Current Ratio | 15.50 |
| Quick Ratio | 15.23 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.52% and return on invested capital (ROIC) is -510.00%.
| Return on Equity (ROE) | -47.52% |
| Return on Assets (ROA) | -28.01% |
| Return on Invested Capital (ROIC) | -510.00% |
| Return on Capital Employed (ROCE) | -38.15% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$929,929 |
| Employee Count | 141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +214.50% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +214.50% |
| 50-Day Moving Average | 38.04 |
| 200-Day Moving Average | 31.91 |
| Relative Strength Index (RSI) | 31.31 |
| Average Volume (20 Days) | 979,455 |
Short Selling Information
The latest short interest is 3.80 million, so 6.87% of the outstanding shares have been sold short.
| Short Interest | 3.80M |
| Short Previous Month | 3.89M |
| Short % of Shares Out | 6.87% |
| Short % of Float | 11.42% |
| Short Ratio (days to cover) | 2.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -142.90M |
| Pretax Income | -131.12M |
| Net Income | -131.12M |
| EBITDA | -140.50M |
| EBIT | -142.90M |
| Earnings Per Share (EPS) | -$3.05 |
Full Income StatementBalance Sheet
The company has $341.92 million in cash and $23.31 million in debt, giving a net cash position of $318.61 million or $5.77 per share.
| Cash & Cash Equivalents | 341.92M |
| Total Debt | 23.31M |
| Net Cash | 318.61M |
| Net Cash Per Share | $5.77 |
| Equity (Book Value) | 354.97M |
| Book Value Per Share | 7.20 |
| Working Capital | 327.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$111.94 million and capital expenditures -$794,000, giving a free cash flow of -$112.73 million.
| Operating Cash Flow | -111.94M |
| Capital Expenditures | -794,000 |
| Depreciation & Amortization | 2.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -112.73M |
| FCF Per Share | -$2.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |